d.planchard
@dplanchard
Thoracic Oncologist - Prof at University Paris Saclay - Head of Thoracic Group, Medical Oncology Dpt- Gustave Roussy - Villejuif - France 🇫🇷 and INSERM U981
FLAURA2 Regimen as a New Standart of Care for EGFRm NSCLC - @dplanchard oncodaily.com/science/flaura… #NSCLC #EGFRm #LungCancer #LCSM #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews
Informative retrospective study for our NSCLC BRAF patients, great to see this from our German colleagues !
Treatment outcome of NSCLC patients with BRAFnon-V600Emutations: a retrospective, multicentre analysis within the nNGM Lung Cancer in Germany in @ESMO_Open. Different results with targeted therapies by mutation type even among non-V600E NSCLC. esmoopen.com/article/S2059-…
FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update! astrazeneca.com/media-centre/p…
🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️@AstraZeneca @OncoAlert @Larvol #EGFR @EGFRResisters astrazeneca.com/media-centre/p…
PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as 1st-line Treatment in Pts with EGFRm Advanced NSCLC (FLAURA2) by Prof. Pasi Janne. Very important but huge space open for discussion. We need mature PFS2 and OS to discuss with pts. #LCSM #WCLC23 @IASLC @OncoAlert
News From Industry/ FLAURA2 Update Source AstraZeneca buff.ly/IxqmQjH Long-term follow-up from the Phase III FLAURA2 trial confirms that combining osimertinib with platinum-based chemotherapy and pemetrexed significantly improves overall survival in patients with…
What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line ! We look forward to seeing the final OS data... #EGFR #lungcancer
Departure of a Giant of Genito-urinary Oncology from Gustave Roussy - David Planchard @dplanchard oncodaily.com/blog/david-pla… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews
Departure of a GIANT of genito-urinary oncology from @GustaveRoussy, Prof. Karim Fizazi... A page is turned for Urology Committee, and the next one will be a challenge to write, but many young talents are there and ready to take over. All the best for Karim's future career ...
Very nice ceremony to award the insignia of chevalier à l'ordre du mérite to our CEO @barlesi by the President of Senate in presence of ministers and Madame Brigitte Macron. Congratulations Fabrice, so well deserved for all you've done and contributed to @GustaveRoussy !
A wonderful day of presentations and discussions on thoracic oncology at @hosp_einstein with @mihaela_aldea @GustaveRoussy @FernandoOnco Thank you @gustavoschv for the invitation and the impressive organization of this meeting. Very impressive modern center, superb working tool !
Great day in Hospital Israelita Albert Einstein with great names in #thoraciconcology @dplanchard @mihaela_aldea @NarjustFlorezMD @gustavoschv
Thanks again for the invitation, it's an honor to be here at the Albert Einstein Hospital 🇧🇷 to discuss ADCs!
@dplanchard from @GustaveRoussy talks about ADC in #lcsm We need biomarkers to guide use @OncoAlert @NarjustFlorezMD
Superb presentations and discussion this morning of our EGFRmut patients with our Brazilian colleagues here at the Hospital Albert Einstein Center (Sao-Paulo) @hosp_einstein. A pleasure to be present with @mihaela_aldea Thanks for the invitation! @GustaveRoussy
It's going to be a great lung session @myESMO, like every year! Happy to share this with @DrJNaidoo @caliraf and our young oncologists…
Excited to serve as @myESMO faculty for the #ESMOAcademy 2025 📅 22-24 Aug 📍 Prague, Czech Republic Join us as we review the A-Z of oncology, & help prepare for the ESMO exam 📝 @dplanchard @caliraf @amanda_psyrri @curijoey @RuhlmannC @CancerCentreIre @RCPI_Trainees…
Superb welcome here in Mexico for the @SMEOMX conference, with a morning of controversies dedicated to thoracic oncology on strategies for early and locally advanced stages, as well as AGAs pts... A pleasure to bring a bit of France to the discussions ! #lungcancer #egfr
Qx raise about role of ADCs in NSCLC. Data in NSCLC and AGA🧬most in mEGFR at osimertinib. but should be applied as monotherapy? With osimertinib? Some data in NSCLC with other AGA but no intracranial data. There is a room for improvement. We need to define the population
A great day for our French 🇫🇷 @IFCTlung intergroup ! #lungcancer
Thanks organizing these joint meeting with different industries, scientists and medical oncologists like me to talk about Antibody Conjuguates. We need to work together to develop wave of new trtts that are coming for our pts (but still too little market access). #lungcancer
Excellent radiotherapy/systematic treatment pairing with Drs A.Levy and E.Pons-Tostivint for the latest in localized SCLC treatment .... it's progressing too ! @IFODS_CONGRESS
Great review of the latest advances in small cells lung cancer by @LGreillier ...impressive recent advances in this disease! @IFODS_CONGRESS
